September 6, 2013 / 4:36 PM / in 4 years

U.S. FDA approves Celgene's Abraxane for pancreatic cancer

Sept 6 (Reuters) - Celgene Corp’s drug Abraxane was approved as a treatment for pancreatic cancer by the U.S. Food and Drug Administration on Friday.

Abraxane is currently approved to treat breast cancer and non-small cell lung cancer. In a clinical trial, patients with pancreatic cancer who received Abraxane plus the chemotherapy gemcitabine lived, on average, 1.8 months longer than those who received gemcitabine alone.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below